Novel de novo POLR3B mutations responsible for demyelinating Charcot-Marie-Tooth disease in Japan.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
10
03
2022
received:
16
12
2021
accepted:
24
03
2022
pubmed:
29
4
2022
medline:
11
5
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
Biallelic POLR3B mutations cause a rare hypomyelinating leukodystrophy. De novo POLR3B heterozygous mutations were recently associated with afferent ataxia, spasticity, variable intellectual disability, and epilepsy, and predominantly demyelinating sensorimotor peripheral neuropathy. We performed whole-exome sequencing (WES) of DNA samples from 804 Charcot-Marie-Tooth (CMT) cases that could not be genetically diagnosed by DNA-targeted resequencing microarray using next-generation sequencers. Using WES data, we analyzed the POLR3B mutations and confirmed their clinical features. We identified de novo POLR3B heterozygous missense mutations in two patients. These patients presented with early-onset demyelinating sensorimotor neuropathy without ataxia, spasticity, or cognitive impairment. Patient 1 showed mild cerebellar atrophy and spinal cord atrophy on magnetic resonance imaging and eventually died of respiratory failure in her 50s. We classified these mutations as pathogenic based on segregation studies, comparison with control database, and in silico analysis. Our study is the third report on patients with demyelinating CMT harboring heterozygous POLR3B mutations and verifies the pathogenicity of POLR3B mutations in CMT. Although extremely rare in our large Japanese case series, POLR3B mutations should be added to the CMT-related gene panel for comprehensive genetic screening, particularly for patients with early-onset demyelinating CMT.
Sections du résumé
BACKGROUND
Biallelic POLR3B mutations cause a rare hypomyelinating leukodystrophy. De novo POLR3B heterozygous mutations were recently associated with afferent ataxia, spasticity, variable intellectual disability, and epilepsy, and predominantly demyelinating sensorimotor peripheral neuropathy.
METHODS
We performed whole-exome sequencing (WES) of DNA samples from 804 Charcot-Marie-Tooth (CMT) cases that could not be genetically diagnosed by DNA-targeted resequencing microarray using next-generation sequencers. Using WES data, we analyzed the POLR3B mutations and confirmed their clinical features.
RESULTS
We identified de novo POLR3B heterozygous missense mutations in two patients. These patients presented with early-onset demyelinating sensorimotor neuropathy without ataxia, spasticity, or cognitive impairment. Patient 1 showed mild cerebellar atrophy and spinal cord atrophy on magnetic resonance imaging and eventually died of respiratory failure in her 50s. We classified these mutations as pathogenic based on segregation studies, comparison with control database, and in silico analysis.
CONCLUSION
Our study is the third report on patients with demyelinating CMT harboring heterozygous POLR3B mutations and verifies the pathogenicity of POLR3B mutations in CMT. Although extremely rare in our large Japanese case series, POLR3B mutations should be added to the CMT-related gene panel for comprehensive genetic screening, particularly for patients with early-onset demyelinating CMT.
Identifiants
pubmed: 35482004
doi: 10.1002/acn3.51555
pmc: PMC9082381
doi:
Substances chimiques
POLR3B protein, human
EC 2.7.7.6
RNA Polymerase III
EC 2.7.7.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
747-755Informations de copyright
© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Neurol Genet. 2018 Dec 03;4(6):e289
pubmed: 30584594
Am J Hum Genet. 2011 Nov 11;89(5):652-5
pubmed: 22036172
Eur J Neurol. 2011 Jan;18(1):39-48
pubmed: 20482598
Cell Cycle. 2010 Sep 15;9(18):3687-99
pubmed: 20890107
Eur J Neurol. 2017 Oct;24(10):1274-1282
pubmed: 28771897
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Am J Hum Genet. 2011 Sep 9;89(3):415-23
pubmed: 21855841
Brain. 2019 Aug 1;142(8):2215-2229
pubmed: 31199454
J Peripher Nerv Syst. 2014 Dec;19(4):311-6
pubmed: 25583183
Nat Commun. 2015 Jul 07;6:7623
pubmed: 26151409
J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):195-202
pubmed: 30257968
BMC Neurol. 2021 Oct 20;21(1):402
pubmed: 34666706
Pediatr Neurol. 2000 Oct;23(4):349-51
pubmed: 11068170
Rev Neurol (Paris). 2016 Dec;172(12):775-778
pubmed: 27866730
Am J Hum Genet. 2021 Jan 7;108(1):186-193
pubmed: 33417887
Ann Clin Transl Neurol. 2020 Oct;7(10):1962-1972
pubmed: 32949214
Brain. 2011 Jun;134(Pt 6):1839-52
pubmed: 21576112